Respiratory health
We understand that respiratory care is not only about managing the symptoms of respiratory diseases, but also about protecting the air we breathe. Air quality and climate change can directly affect people living with respiratory conditions.(1) At the same time, the way treatments are developed and delivered can also have an environmental impact.
At Chiesi, our ambition is clear: to keep advancing respiratory care while acting responsibly towards people and the planet.
For more than 40 years, we have focused on supporting people living with asthma, chronic obstructive pulmonary disease (COPD), and other chronic respiratory diseases. This long-standing experience has shaped how we approach respiratory care today: combining scientific knowledge with a deep understanding of what it means to live with a respiratory condition.
Through continuous investment in research and development, we work to discover and improve treatments that can support better outcomes in everyday life. From helping people manage breathlessness to supporting independence and quality of life, we focus on what matters most to patients, carers, and healthcare professionals, while recognising that lung health and planetary health are connected, and that our responsibility is to create lasting, positive impact.
Living with a respiratory condition is not only about managing symptoms. It affects how people move, sleep, work, and take part in everyday life. That is why our approach focuses on supporting people beyond the clinical definition of these diseases, combining treatment, understanding of the complexity of their experience, and long-term care.
Asthma
Asthma is a chronic inflammatory disease that affects the airways and can cause breathlessness, wheezing, and coughing.(6) Symptoms can vary from day to day and may be triggered by factors such as allergens, exercise, respiratory infections, or air quality.(3,7)
We develop therapies and inhaler technologies designed to support better symptom management and disease control. Through research and patient-centred strategies, we aim to improve outcomes and support quality of life.
Chronic Obstructive Pulmonary Disease (COPD)
Chronic obstructive pulmonary disease (COPD) is a long-term respiratory disease that causes airflow limitation and can make everyday breathing more difficult over time.(5) For many people, COPD can affect daily activities such as walking, climbing stairs, or sleeping well, and symptoms may worsen during exacerbations.(5)
We develop therapies and inhaler technologies designed to support symptom management, help reduce the impact of exacerbations and address the everyday challenges of living with COPD.
Chiesi appoints David Khougazian as Group Chief Executive Officer to lead the next phase of innovation-driven growth
Highlights: David Khougazian appointed Group Chief Executive Officer to lead Chiesi's next phase of innovation-driven growth, effective 15 October 2026. Bringing over 25 years of international healthcare leadership experience and a strong track record in innovation and transformation, David joins…
Chiesi Group delivers solid H1 2026 performance, combining growth, continued investment in innovation and positive economic impact across communities
HIGHLIGHTS H1 2026 revenues of €1.89 billion, up + 3.6% at CER versus H1 2025, driven by growth in the inhaled triple therapy portfolio and strong momentum in the rare diseases therapeutic area Continued investment in innovation with €426 million invested in R&D (22.5% of sales) Completed strategic…
Chiesi advances its Carbon Minimal Inhaler journey as European submissions for its Single Inhaler Triple Therapy (SITT) and ICS/LABA combination next-generation propellant pMDIs are validated
Key Highlights Regulatory submissions for next-generation propellant pMDIs (pressurized metered-dose inhalers) across Chiesi’s Single Inhaler Triple Therapy (SITT; or ICS/LABA/LAMA) and fixed double ICS/LABA combination (inhaled corticosteroid with a long-acting bronchodilator) range have been…
Chiesi receives European Marketing Authorisation for its Single Inhaler Triple Therapy delivered via NEXThaler® for the maintenance treatment of Asthma
Key Highlights This European Authorisation reinforces Chiesi’s commitment to provide a broad range of formulations and devices to asthma patients. NEXThaler® is a dry powder inhaler (DPI), specifically designed for Chiesi’s extrafine formulations. With the addition of the DPI in the asthma…
Chiesi Global Rare Diseases Announces European Commission Approval of LOJUXTA® (lomitapide) ▼ Capsules for Paediatric Use in Homozygous Familial Hypercholesterolaemia (HoFH)
PARMA, Italy – June 5, 2026 – Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, today announced that the European Commission (EC) has approved lomitapide capsules for use in children 5…
Chiesi completes the KalVista acquisition
Parma, Italy and Framingham, Mass., USA – 11 June, 2026 – Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, today announced the completion of its acquisition of KalVista Pharmaceuticals, Inc. (“KalVista”). KalVista is now part of Chiesi Group…
Chiesi Group Announces New Chair and Vice Chair
Highlights: Planned transition in the Chair and Vice Chair roles reflects the Chiesi family’s long-term commitment to continuity, shared value and responsible governance across generations Maria Paola Chiesi is appointed Chair, the first woman in this role; aims to reinforce sustainability as an…
Chiesi to acquire KalVista Pharmaceuticals
Highlights: Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equity consideration of approximately $1.9bn Acquisition adds to Chiesi’s rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi’s…
Chiesi's FY2025 results and a leadership transition
Highlights: Strong FY2025 financial and sustainability results; leadership transition will support continuity and long-term growth Revenue up 8.2% to €3.6bn with double-digit growth in Rare Diseases and U.S. market Air sales at €1.886bn, growing 3.9% vs. 2024 - Care sales at €904m growing 13.3% vs.…
Chiesi selects Salesforce Agentforce Life Sciences
International biopharmaceutical leader accelerates digital transformation with AI-powered customer engagement, unified data, and next-generation integration capabilities APRIL 20, 2026 – Chiesi Group, an international biopharmaceutical group, has selected Salesforce’s Agentforce Life Sciences for…
References
1 Economist enterprise: Cleaner air, clearer lungs, better lives: exploring the intersection of air quality, health inequalities and lung health: https://insights.economistenterprise.com/health-society/cleaner-air-clearer-lungs-better-lives
2 World Health Organization - Asthma: https://www.emro.who.int/health-topics/asthma/
3 GINA - Global Strategy for Asthma Management and Prevention: https://ginasthma.org/wp-content/uploads/2025/11/GINA-2025-Update-25_11_08-WMS.pdf
4 Boer E, et al. Global Burden of Chronic Obstructive Pulmonary Disease Through 2050. JAMA Netw Open. 2023;6:e2346598: https://pubmed.ncbi.nlm.nih.gov/38060225/
5 World Health Organization - Chronic Obstructive Pulmonary Disease (COPD): https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)
6 World Health Organization - Asthma Factsheet: https://www.who.int/news-room/fact-sheets/detail/asthma
7 NICE - When should I suspect a diagnosis of asthma?: https://cks.nice.org.uk/topics/asthma/diagnosis/diagnosis/